| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
736.57(B) |
| Last
Volume: |
1,669,189 |
Avg
Vol: |
3,285,540 |
| 52
Week Range: |
$423.21 - $792.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
750 |
870,750 |
2,710,260 |
6,110,274 |
| Total Sell Value |
$565,200 |
$608,250,580 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
1 |
2 |
5 |
6 |
| Total Sell Transactions |
1 |
13 |
42 |
86 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lilly Endowment Inc |
10% Owner |
– – • |
2021-08-03 |
4 |
S |
$256.03 |
$60,582,474 |
D/D |
(236,542) |
108,525,558 |
|
5% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-07-21 |
4 |
S |
$237.00 |
$20,408,307 |
D/D |
(86,111) |
108,762,100 |
|
-10% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-07-20 |
4 |
S |
$237.06 |
$3,700,429 |
D/D |
(15,610) |
108,848,211 |
|
-11% |
|
| Johnson Kimberly H |
Director |
– • – |
2021-07-19 |
4 |
A |
$234.14 |
$9,600 |
D/D |
41 |
235 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2021-07-19 |
4 |
A |
$234.14 |
$11,005 |
D/D |
47 |
49,849 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2021-07-19 |
4 |
A |
$234.14 |
$1,873 |
D/D |
8 |
61,274 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-07-14 |
4 |
S |
$237.02 |
$2,555,119 |
D/D |
(10,780) |
108,863,821 |
|
-11% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-07-12 |
4 |
S |
$237.09 |
$767,694 |
D/D |
(3,238) |
108,874,601 |
|
-9% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-07-09 |
4 |
S |
$237.30 |
$25,937,091 |
D/D |
(109,261) |
108,877,839 |
|
-10% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-07-06 |
4 |
S |
$235.09 |
$49,369,047 |
D/D |
(210,000) |
108,987,100 |
|
-12% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-07-02 |
4 |
S |
$232.69 |
$47,077,749 |
D/D |
(202,102) |
109,197,100 |
|
-12% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-06-24 |
4 |
S |
$237.45 |
$3,063,401 |
D/D |
(12,898) |
109,399,202 |
|
-7% |
|
| Alvarez Ralph |
Director |
– • – |
2021-06-21 |
4 |
A |
$222.67 |
$10,911 |
D/D |
49 |
49,802 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2021-06-21 |
4 |
A |
$222.67 |
$9,575 |
D/D |
43 |
194 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2021-06-21 |
4 |
A |
$222.67 |
$2,004 |
D/D |
9 |
61,266 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-06-10 |
4 |
S |
$232.35 |
$56,072,352 |
D/D |
(240,000) |
109,412,100 |
|
-2% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-06-09 |
4 |
S |
$223.90 |
$49,484,263 |
D/D |
(220,000) |
109,652,100 |
|
-5% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-06-07 |
4 |
S |
$219.09 |
$51,685,008 |
D/D |
(230,000) |
109,872,100 |
|
-6% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-05-24 |
4 |
S |
$201.78 |
$1,482,405 |
D/D |
(7,329) |
110,102,100 |
|
-15% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-05-21 |
4 |
S |
$200.26 |
$18,602,006 |
D/D |
(92,740) |
110,109,429 |
|
-16% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-05-20 |
4 |
S |
$200.46 |
$20,033,767 |
D/D |
(99,931) |
110,202,169 |
|
-15% |
|
| Johnson Kimberly H |
Director |
– • – |
2021-05-17 |
4 |
A |
$195.53 |
$9,581 |
D/D |
49 |
151 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2021-05-17 |
4 |
A |
$195.53 |
$10,950 |
D/D |
56 |
49,573 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2021-05-17 |
4 |
A |
$195.53 |
$1,955 |
D/D |
10 |
61,205 |
|
- |
|
| Hernandez Edgardo |
SVP & Pres., Mfg. OperationsOf |
• – – |
2021-05-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
838 |
|
29% |
|
306 Records found
|
|
Page 12 of 13 |
|
|
1.12 (0.15%) 
